Core Viewpoint - Corning Jereh Pharmaceutical-B (09966) has seen a nearly 5% increase in stock price, attributed to the announcement of FDA granting Breakthrough Therapy Designation (BTD) for JSKN003, a treatment for specific types of ovarian cancer in patients previously treated with bevacizumab [1][1][1] Group 1: Company Developments - JSKN003 has received BTD from the FDA for treating platinum-resistant recurrent epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube cancer in adults who have previously undergone bevacizumab treatment [1][1] - Prior to this, JSKN003 was approved by the FDA to conduct a Phase II clinical trial for treating PROC regardless of HER2 expression levels [1][1] - The drug has also received BTD from the National Medical Products Administration (NMPA) for PROC and colorectal cancer (CRC), as well as Fast Track designation and orphan drug status from the FDA for gastric/gastroesophageal junction cancer (GC/GEJ) [1][1][1] Group 2: Market Reaction - Following the announcement, Corning Jereh Pharmaceutical-B's stock price rose by 4.87%, reaching HKD 11.19, with a trading volume of HKD 8.53 million [1][1]
港股异动 | 康宁杰瑞制药-B(09966)再涨近5% JSKN003已获FDA授予突破性疗法认定